Efficacy and Safety of Sarilumab for Noninfectious Uveitis of Posterior Segment: Outcomes From the Phase 2 SATURN Trial
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Ophthalmology |
| Citation | |
| Web | http://dx.doi.org/10.1016/j.ophtha.2018.09.044 |
| Doi | http://dx.doi.org/10.1016/j.ophtha.2018.09.044 |
| Keywords | Sarilumab, rear uveitis, anti-interleukin-6 receptor antibody |
| Description | To assess efficacy and safety of sarilumab, a human anti-interleukin-6 receptor antibody, for treatment of posterior segment noninfectious uveitis (NIU).Subcutaneous sarilumab may provide clinical benefits in the management of NIU of the posterior segment, especially in eyes with uveitic macular edema. |